Session Information
Session Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Treatment and Management Studies
Session Type: Abstract Submissions (ACR)
Background/Purpose:
Cervical neoplasia is increased in women with SLE presumably due to cervical infection with oncogenic Human Papillomavirus (HPV) types which persist in an immunosuppressed host. Vaccinating women with SLE against HPV is thus an important part of health prevention in this population. Gardasil® immunizes against the HPV types that cause the majority of cervical cancer (types 16 and 18) and genital warts (types 6 and 11), and has been shown to be protective against these HPV-related diseases.
Methods:
For this ongoing trial, 36 women ages 19-50 years with a history of mild to moderate SLE and minimally active or inactive SLE disease received Gardasil® at the standard dosing schedule (0, 2 months, 6 months). This study was approved by the Human Investigation Committee at Wayne State University and the U.S. Food and Drug Administration. Patients were excluded if they had active disease (SELENA-SLEDAI >2), a history of severe disease, deep venous thrombosis, were on >400 mg/day of hydroxychloroquine, were on >15 mg/day of prednisone, or had active infections. To date, all 36 patients have completed the vaccine series shots. Patients were monitored for adverse events (AE), SLE flare, and generation of thrombogenic antibodies and thrombosis.
Results:
The women in the study were predominantly African-American (81%), mean age 38.4 years with mean age at diagnosis of SLE at 29.4 years. All patients met American College of Rheumatology (ACR) criteria for SLE; 24.3% had a history of smoking, 92% had 4 or more sexual partners, 38.9% had a history of sexually transmitted diseases, and only 30.6% used condoms on a regular basis. History of abnormal pap smears occurred in 44.4% ranging from ASCUS (atypical glandular cells of undetermined significance) to CIN 3 (cervical intraepithelial neoplasia grade 3). Most of our patients had multiple comorbidities in addition to SLE. Vaccine site reactions (VSRs) occurred in 55%, all being mild, with the most common reaction being pain. This compares favorably to data from the current prescribing label showing frequency of VSRs in normal women to be 83.9% for Gardasil® vs. 75.4% for controls. For the non-vaccine site adverse events (nvAE), 90% of our cohort experienced at least one nvAE; there were 467 nvAEs reported from 36 patients and 90% of these nvAEs were mild. There were 9 serious adverse events, none were related to vaccine or SLE and all resolved. The most common nvAEs reported were musculoskeletal (n=99) followed by nervous system (n=93, mostly headaches), gastrointestinal (n=46), general disorders (n=46) and dermatologic (n=45). None of the nvAEs were related to vaccine or SLE. There was no flare of SLE, thrombosis, or generation of thrombogenic antibodies in any patient.
Conclusion:
Preliminary data from our study shows that Gardasil® vaccine is safe to use in women with SLE. Vaccine site reactions are not increased in SLE patients. Other than vaccine site reactions, there were no related short term adverse events. Gardasil® vaccine administration did not result in any lupus flare or thrombosis. Women with SLE should be immunized with Gardasil® vaccine as part of their health prevention program, particularly since this population is at increased risk for HPV-related cervical dysplasia.
Disclosure:
J. P. Dhar,
Merck, Inc,
2;
L. Essenmacher,
None;
R. Dhar,
None;
A. Magee,
Merck, INc,
9;
H. Sagar,
None;
M. Venkatram,
None;
R. Sokol,
None.
« Back to 2014 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/safety-of-gardasil-vaccine-in-systemic-lupus-erythematosu-trial-update/